MPS II

Neurology·MeSH: Sudden Infant Death

10 drugs in development·5 companies·1 clinical trial

Drug Pipeline by Phase

Approved(1)

Drug	Company
avlayah	Denali Therapeutics Inc. (DNLI)

Phase 3(4)

BLA Filed(1)

Drug	Company
UX111 (ABO-102)	ABEONA THERAPEUTICS INC. (ABEO)

Phase 2/Phase 3(4)

Drug	Company
Adjuvant IM Therapy	Ultragenyx Pharmaceutical Inc. (RARE)
Optimized Prophylactic IM Therapy	Ultragenyx Pharmaceutical Inc. (RARE)
Prophylactic Immunomodulatory Therapy	Ultragenyx Pharmaceutical Inc. (RARE)
UX111	Ultragenyx Pharmaceutical Inc. (RARE)

BioSniper tracks 10 drugs in development for MPS II across 5 companies.

There are 1 clinical trial targeting MPS II tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.